[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589875":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":22,"locations":28,"responsibleParty":47,"collaborators":49,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with Parkinson's Disease undergoing DBS",null,[12],"Other: DBS combined with fMRI",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"DBS combined with fMRI","Participants will undergo fMRI scanning while their DBS device is either turned OFF or ON. BOLD (blood oxygen level dependent) changes in response to DBS will be evaluated across PD participants. These scans and DBS procedure will be used for research purposes only and are not for treatment or diagnostic purposes.",[9],[19],{"name":20,"affiliation":5,"role":21},"Daniel Lench, PhD","PRINCIPAL_INVESTIGATOR",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Recruitment Coordinator","CONTACT","843-792-0235","malakout@musc.edu",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Charleston","South Carolina","29425","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-79.93275,32.77632,{"lat":40,"lon":39},[43],{"name":44,"role":25,"phone":45,"phoneExt":10,"email":46},"Daniel H. Lench, Phd","843-792-9115","lenchd@musc.edu",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[50],{"name":51,"class":52},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH","100589875","cognitive-decline-following-deep-brain-stimulation-a-dbs-fmri-study-100589875",false,"NCT06960096","Cognitive Decline Following Deep Brain Stimulation: A DBS-fMRI Study","A Neural Basis for Cognitive Decline Following Deep Brain Stimulation: A DBS-fMRI Study","Inclusion Criteria:\n\n* Subjects above 18 years of age\n* Individuals with a PD diagnosis as defined by the UK Brain Bank diagnostic criteria for Parkinson's disease (58) which have undergone a neurological and neuropsychological evaluation at MUSCs movement disorder center, and were selected to undergo 3T compatible unilateral or bilateral STN- DBS implants\n\nExclusion Criteria:\n\n* Uncorrected visual or hearing impairments, as indicated by self-report\n* Individuals who are pregnant or expect to become pregnant during the course of the study\n* Individuals that have a history of neurological disease (other than PD) including previous stroke, major head trauma, and epilepsy or seizures.\n* Individuals with claustrophobia, or the inability to lie supine position in the MRI scanner\n* COPD with oxygen dependence\n* Non-MRI compatible metal implants (surgical clips or staples, cardiac pacemakers etc.)",true,"ALL","18 Years",{"count":64,"type":65},55,"ESTIMATED","OBSERVATIONAL","The objective of this research study is to understand how Deep Brain Stimulation (DBS) targeting the subthalamic nucleus (STN) affects cognitive networks in the brain, potentially leading to cognitive decline in patients with Parkinson's Disease (PD). A total of 55 participants with PD who have undergone DBS surgery will be recruited from MUSC's Clinical DBS Program. Participants will attend two post-DBS visits: a 3-hour visit for consent, demographic, and cognitive assessments, and a 3-hour DBS-MRI visit to evaluate brain network connectivity with stimulation ON and OFF. These findings will help improve patient selection for surgery and optimize the selection of stimulation targets that minimize undesirable cognitive side effects.",[69,70],"Deep Brain Stimulation","Parkinson Disease",[72,73,74,75],"Brain","Parkinsons","deep brain stimulation","Cognitive","2025-10-10",{"date":78,"type":79},"2025-10-14","ACTUAL",{"date":81,"type":79},"2025-08-21",{"date":83,"type":65},"2028-04-01",{"name":5,"class":6},1]